TRIAL OF URIDINE SUPPLEMENTATION IN HIV LIPOATROPHY
补充尿苷治疗 HIV 脂肪萎缩的试验
基本信息
- 批准号:7625481
- 负责人:
- 金额:$ 0.19万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2007
- 资助国家:美国
- 起止时间:2007-04-23 至 2007-11-30
- 项目状态:已结题
- 来源:
- 关键词:ButtocksComputer Retrieval of Information on Scientific Projects DatabaseDouble-Blind MethodEuropeFaceFatty acid glycerol estersFood SupplementsFundingGrantHIV-1InstitutionJuiceLegLimb structureLipoatrophyMilkNutritionalPersonsPharmaceutical PreparationsPhasePopulationPowder dose formRandomizedResearchResearch PersonnelResourcesRetrovirSafetySourceStavudineSupplementationUnited States Food and Drug AdministrationUnited States National Institutes of HealthUpper armUridineWaterZidovudineantiretroviral therapyplacebo controlled study
项目摘要
This subproject is one of many research subprojects utilizing the
resources provided by a Center grant funded by NIH/NCRR. The subproject and
investigator (PI) may have received primary funding from another NIH source,
and thus could be represented in other CRISP entries. The institution listed is
for the Center, which is not necessarily the institution for the investigator.
A5229 is a Phase II/III, randomized, double-blind, placebo-controlled study of uridine supplementation in the form of NucleomaxXfor the treatment of HIV-associated lipoatrophy. This study will examine the effect of NucleomaxX on limb fat in HIV-1 infected subjects receiving stable antiretroviral therapy (ART) containing stavudine (Zerit¿) or zidovudine (Retrovir¿). The study will also assess the safety and tolerability of NucleomaxX in this population.
This study will try to see if taking uridine is safe in HIV-infected persons and if it will reverse loss of fat in the face, arms, legs, or buttocks. The study will also try to see how well uridine is tolerated. Uridine is a powdered nutritional food supplement that contains a substance called uridine. It comes in a sachet (packet) and needs to be mixed in with juice, milk, or water. Uridine is used in Europe as a food supplement but is not approved by the U.S. Food and Drug Administration (FDA) and is considered an experimental drug in the U.S.
这个子项目是许多研究子项目中利用
资源由NIH/NCRR资助的中心拨款提供。子项目和
调查员(PI)可能从NIH的另一个来源获得了主要资金,
并因此可以在其他清晰的条目中表示。列出的机构是
该中心不一定是调查人员的机构。
A5229是一项II/III期的随机、双盲、安慰剂对照研究,以Nucleomax X的形式补充尿苷,用于治疗HIV相关性脂肪萎缩。这项研究将考察接受包含司他夫定(Zerit?)或齐多夫定(Retrovir?)的稳定抗逆转录病毒疗法(ART)的HIV-1感染者的Nucleomax X对肢体脂肪的影响。这项研究还将评估NucleomaxX在该人群中的安全性和耐受性。
这项研究将试图了解在HIV感染者中服用尿苷是否安全,以及它是否会逆转面部、手臂、腿部或臀部的脂肪损失。这项研究还将试图了解尿苷的耐受性。尿苷是一种粉状营养食品补充剂,含有一种名为尿苷的物质。它是装在香包里的,需要和果汁、牛奶或水混合。尿苷在欧洲被用作食品补充剂,但没有得到美国食品和药物管理局(FDA)的批准,在美国被认为是一种实验药物。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
DAVID WININGER其他文献
DAVID WININGER的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('DAVID WININGER', 18)}}的其他基金
CLINICAL TRIAL: TRIAL OF URIDINE SUPPLEMENTATION IN HIV LIPOATROPHY
临床试验:补充尿苷治疗 HIV 脂肪萎缩的试验
- 批准号:
7718655 - 财政年份:2007
- 资助金额:
$ 0.19万 - 项目类别:
A5082: A STUDY OF METFORMIN AND ROSIGLITAZONE IN HIV-INFECTED PATIENTS
A5082:二甲双胍和罗格列酮治疗 HIV 感染患者的研究
- 批准号:
7198621 - 财政年份:2004
- 资助金额:
$ 0.19万 - 项目类别:
A Study Of Metformin & Rosiglitazone in HIV-Infected Pts
二甲双胍的研究
- 批准号:
7011503 - 财政年份:2003
- 资助金额:
$ 0.19万 - 项目类别: